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Abstract
Background: Neuroblastic tumors include the neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. Clinical
behavior of these developmental malignancies varies from regression to aggressive growth with metastatic dissemination.
Several clinical, histological, genetic, and biological features are associated with this diversity of clinical presentations. The
calcium-sensing receptor (CaSR) is a G-protein coupled receptor with a key role in calcium homeostasis. We have previously
reported that it is expressed in benign, differentiated neuroblastic tumors, but silenced by genetic and epigenetic events in
unfavorable neuroblastomas. We have now analyzed three functionally relevant polymorphisms clustered at the signal
transduction region of the CaSR (rs1801725, rs1042636 and rs1801726) to assess if genetic variants producing a less active
receptor are associated with more aggressive disease course.
Methods: Polymorphisms were analyzed in DNA samples from 65 patients using specific Taqman Genotyping Assays.
Results: Mildly inactivating variant rs1801725 was associated with clinical stage 4 (P= 0.002) and the histological subgroup
of undifferentiated neuroblastomas (P= 0.046). Patients harboring this polymorphism had significantly lower overall
(P = 0.022) and event-free survival (P= 0.01) rates than those who were homozygous for the most common allele among
Caucasians. However, this single locus genotype was not independently associated with outcome in multivariate analyses.
Conversely, the tri-locus haplotype TAC was independently associated with an increased risk of death in the entire cohort
(Hazard Ratio = 2.45; 95% Confidence Interval [1.14–5.29]; P = 0.022) and also in patients diagnosed with neuroblastomas
(Hazard Ratio = 2.74; 95% Confidence Interval [1.20–6.25]; P= 0.016).
Conclusions: The TAC haplotype includes the moderately inactivating variant rs1801725 and absence of the gain-of-
function rs1042636 polymorphism. Thus, its association with metastatic disease and poor outcome would add to our
previous data and further support that inactivation of the CaSR gene is a mechanism associated with neuroblastoma
malignant behavior.
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Introduction
Neuroblastic tumors are developmental malignancies that arise
from peripheral nervous system precursor cells and include the
neuroblastomas, ganglioneuroblastomas and ganglioneuromas.
Some of these tumors undergo spontaneous regression, others
develop as a localized mass and a third group proliferate
aggressively and invade organs distant from primary site [1]. A
number of clinical, histological, genetic and biological factors are
associated with this variety of clinical presentations, including age
at diagnosis, clinical stage, histological classification, amplification
of the oncogene MYCN, alterations of ploidy and abnormalities at
the chromosomal region 11q [2–4].
The calcium ion (Ca2+) plays a key role in a variety of
physiological functions including muscle contraction, coagulation
and synaptic transmission. In cancer, this divalent cation
participates in the control of the balance between cell proliferation
and death [5]. One of the mechanisms that contributes to regulate
the function of Ca2+ in normal and neoplastic cells is the control of
its intracellular and plasmatic levels. This is achieved via a complex
multiorganic system that involves numerous molecules. Among
them, the calcium-sensing receptor (CaSR) is a G-protein coupled
receptor (GPCR) that senses minimal plasmatic fluctuations of
Ca2+ and regulates the secretion of parathyroid hormone and
calcitonin accordingly [6]. The CaSR is also expressed in other
organs involved in calcium homeostasis, in several non-neoplastic
tissues and in a number of malignancies [7,8]. The role of this
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GPCR seems to be cell-type dependent, but the mechanisms
responsible for this diversity of functions are only partially
understood.
The CaSR is composed of three main regions: A large
extracellular domain, where the interaction with the Ca2+ occurs,
a seven transmembrane domain that is a common feature of all
GPCRs, and a carboxyl-terminal intracellular tail, necessary for
Ca2+-mediated activation of G proteins, cell surface expression
and phospholipase C activation, among other functions [9–11].
Naturally-occurring inactivating mutations of the CaSR gene are
the cause of familial hypocalciuric hypercalcemia and neonatal
severe hyperparathyroidism, while activating mutations produce
autosomal dominant hypercalcemia [12–16]. Also, more than 450
single nucleotide polymorphisms (SNPs) have been described in
the CaSR gene. They are divided into three haplotype blocks,
coincident with 59 regulatory, coding and 39 regulatory domains
[17,18]. Three nonsynonymous variants at the intracellular tail
encoded by exon 7 have been identified. The A986S change
encoded by the most common SNP of the CaSR gene in
Caucasians, c.2956 G.T (rs1801725), is considered to produce
a moderately less active receptor [18,19]. The glycine substitution
at arginine-990 encoded by c.2968 A.G (rs1042636) might
induce gain of function [20]. Finally, c.3031 C.G, or Q1011E
(rs1801726), is a common polymorphism in populations with
African ancestry whose functional significance remains to be
established [16,18]. Besides their respective function, specific
haplotypes in this cluster of polymorphisms have been found in
association with blood ionized calcium levels, primary hyperpara-
thyroidism and nephrolitiasis [21–23].
Several studies have analyzed the association of these genetic
variants of the CaSR with risk of colorectal or prostate cancer [24–
30]. However, to the best of our knowledge, a specific haplotype at
these three loci has never been reported as a potential predictor of
outcome in any malignancy.
Our group reported for the first time the expression of the
CaSR in a developmental malignancy. We found that it is
expressed in differentiated, favorable neuroblastic tumors, and up-
regulated upon differentiation induction [31]. Recently, we have
also shown that the CaSR gene is silenced by genetic and epigenetic
mechanisms in unfavorable neuroblastomas [32]. To gain further
insight into the genetic mechanisms responsible for its inactivation
in malignant neuroblastomas, we have now analyzed the three
clustered genetic variants at coding exon 7 that have been
described to influence CaSR activity. Based on our prior data, we
hypothesized that allelic variants encoding a less active receptor
might be associated with poor clinical outcome.
Materials and Methods
Ethics Statement
Written informed consent was obtained from patients, parents
or legal guardians. The protocol was in accordance with the
Declaration of Helsinki and approved by the Ethics Committee for
Clinical Research (Comite´ E´tico de Investigacio´n Clı´nica,
Fundacio´ Sant Joan de De´u, Esplugues de Llobregat, Barcelona).
Patients and Samples
Peripheral blood and bone marrow samples (n = 65) were
collected from all patients newly diagnosed with neuroblastic
tumors at Hospital Sant Joan de De´u, Barcelona, Spain, with
a follow-up time $12 months. Bone marrow samples were only
included in the study if they were free of neuroblastoma cells, as
assessed by PHOX2B mRNA expression analysis (see below). Age
at diagnosis, clinical stage (International Neuroblastoma Staging
System), MYCN amplification status, International Neuroblastoma
Pathology Classification (INPC), ethnicity and time to follow-up
were recorded.
Patients were uniformly treated according to the following
criteria: Stage 4s cases received no cytotoxic therapy unless life-
threatening condition occurred during observation; MYCN non-
amplified stages 1, 2 and 3 tumors were managed exclusively with
surgery unless clinically relevant progression occurred; and stage 4
and MYCN-amplified cases received induction chemotherapy,
second-look surgery, radiotherapy, myeloablative therapy followed
by autologous bone marrow transplant, anti-GD2 immunotherapy
and retinoic acid.
PHOX2B mRNA Expression Analysis
Bone marrow mononuclear cell isolation, total RNA extraction
and cDNA synthesis were carried out as described [33]. Analysis of
PHOX2B mRNA expression was performed following previously
reported procedures [34] in a 7000 Sequence Detection System
(Applied Biosystems). Only samples with a Ct for reference gene
,30 were considered of good quality and then evaluated. Samples
with any amplification of the neuroblastoma-specific PHOX2B
marker were scored as positive and thus matching DNA was
excluded from genotyping analysis.
Genotyping
Genomic DNA was isolated from peripheral blood (n = 41) or
bone marrow (n = 24) mononuclear cells using Qiagen reagents
(Qiagen, Valencia, CA). Polymorphisms were analyzed in a 7500
real-time PCR system (Applied Biosystems) using specific SNP
Genotyping Assays (Applied Biosystems references 7504853 for
rs1801725, 7504854 for rs1042636 and 7504855 for rs1801726),
following manufacturer’s instructions. Genotyping (L.M.), clinical
data recording (C.C.) and statistical analyses (R.I.) were performed
by three independent researchers. For quality control, random
cases (15%) were processed twice in separate runs. Results were
100% concordant.
Statistical Analyses
The x2 and Fisher’s exact tests were used to assess the
association of specific genotypes with clinical and biological
subgroups. Elapsed time from time of diagnosis to an event
(relapse, progression or death) or the end of follow-up was used to
compute event-free survival (EFS) and overall survival (OS)
probabilities, according to the method of Kaplan and Meier
[35]. The log-rank statistic was used to compare the EFS and OS
probabilities between groups [36]. The prognostic significance of
variables was assessed by Cox proportional models [37]. SNPStats
web tool was used to analyze individual SNPs [38]. Homozygous
cases for the most frequent allele were taken as the reference level,
and heterozygous and homozygous cases for the minor allele were
grouped. THESIAS (Testing Haplotype EffectS In Association
Studies) program and BayHap R package were used to compare
OS and EFS probabilities among different haplotype blocks [39–
41]. Haplotype frequencies were estimated in the total cohort, and
separately in the subgroups of alive and dead patients, event and
event-free subgroups. Departure form Hardy-Weinberg equilibri-
um was assessed by means of the Fisher’s exact. Linkage
disequilibrium (LD) between polymorphisms was measured
through D9 and r2. In Cox regression analysis, the most common
haplotype in the sample was taken as the reference level. All
models were adjusted for age at diagnosis, clinical stage and MYCN
amplification status. Additivity of haplotype effects was considered
in all models after performing Likelihood Ratio tests. Analyses
were performed with R 2.14.1, SNPstats or THESIAS programs.
CaSR Polymorphisms and Neuroblastoma Outcome
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P,0.05 was considered significant. Estimates of EFS and OS and
hazard ratio (HR) are presented with 95% confidence intervals
(CI).
This study was conceived to address a single hypothesis, i.e. that
functionally relevant polymorphisms of the CaSR gene influence
neuroblastoma phenotype and thus survival probabilities of
patients. This single hypothesis was tested and proved by means
of a single model. Therefore, results were interpreted without
adjusting for multiple tests [42]. However, the potential clinical
relevance of exploring the entire cohort of patients diagnosed with
neuroblastic tumors and those neuroblastomas without amplifica-
tion of the oncogene MYCN, prompted us to describe survival
probabilities in these patients as well.
Results
CaSR Gene Exon 7 Polymorphisms in Neuroblastic
Tumors
All available patients diagnosed with neuroblastic tumors with
a follow-up time longer than 12 months were included in the study
(n = 65). Their clinical and biological features are summarized in
Table S1 and detailed in Table S2. Median follow-up was 4.4
years (range 12.2 to 124.3 months). All patients but one (#61)
were of Caucasian origin. To ascertain if this cohort was similar to
others, OS and EFS probabilities were calculated according to
well-established clinical and biological parameters in neuroblasto-
ma (Table S1). As expected, clinical stage 4, MYCN amplification
and unfavorable histology were associated with poor outcome. Age
at diagnosis $18 months was correlated with worse OS (P= 0.013)
and EFS (P= 0.001) rates among neuroblastoma patients but not
in the entire cohort, due to the presence of ganglioneuroblastomas
and ganglioneuromas (Table S1 and Table S2).
Statistical associations of single locus genotypes were then
examined. Polymorphism rs1801725, present either in homo- or
heterozygosis, was detected in 22/65 (33.8%) of patients. Genetic
variant rs1042636 was found in 8/65 patients (12.3%) and
rs1801726 was only detected in four patients (6.1%) (Table S2).
The genotype frequencies for all three polymorphisms were in
accordance with Hardy-Weinberg equilibrium (Table S3). Asso-
ciations of single SNPs with clinical and biological features of
neuroblastic tumors are shown in Table 1. The low frequency of
two variants, rs1042636 and rs1801726, precluded the analysis of
statistical correlations with specific subgroups or survival proba-
bilities. Conversely, upon univariate analysis, rs1801725 was found
to be associated with clinical stage 4 (P= 0.002) and the
histological subgroup of undifferentiated neuroblastomas
(P= 0.046). Patients harboring this variant had significantly lower
OS (P= 0.022) and EFS (P= 0.01) rates than those who were
homozygous for the most common allele among Caucasians.
However, this single locus genotype was not independently
associated with outcome in multivariate analyses (Table 2).
Associations of tri-locus haplotypes were then evaluated. Four
haplotypes were found in the entire cohort (Table 3). The most
probable haplotype (GAC) had an estimated frequency of 72%
and was composed of the most frequent alleles among Caucasian
populations, as expected. The estimated frequency of the TAC
haplotype was nearly 20% and lower for two other combinations
(GGC and GAG). Strong LD (D9.0.95) existed between all SNP
pairs with the only exception of rs1801725 and rs1801726 (Table
S4). This result might be influenced by the low frequence of
rs1801726 minor allele in populations of Caucasian origin.
In univariate analysis, the TAC haplotype was correlated with
clinical stage 4 (P= 0.008) and inferior OS rates (P= 0.006)
(Figure 1A). Moreover, in multivariate analyses, the TAC
combination was independently associated with an increased risk
of death in the entire cohort after adjusting for age at diagnosis,
clinical stage and MYCN amplification status (Table 3). This
association was also significant when the analysis was restricted to
patients with a follow-up time longer than three years (HR = 2.19;
95% CI [1.01–4.76]; P= 0.046). An increased risk of events
(P= 0.008) that almost reached significance in multivariate
analyses (P= 0.052) was also observed among patients with the
TAC haplotype (Table 3). Associations of this combination when
present in homozygosis were not analyzed separately due to their
very low frequency.
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The subgroup of neuroblastoma patients (n = 54) was then
analyzed separately according to single locus genotypes and tri-
locus haplotypes. Associations of single SNPs with clinical and
biological features of neuroblastomas are shown in Table S5.
Again, rs1801725 variant, present either in homo- or heterozy-
gosis, was associated with clinical stage 4 (P= 0.02) and inferior
OS rates (P= 0.023). However, this polymorphism was not an
independent predictor of outcome in multivariate analyses, after
adjusting for age at diagnosis, clinical stage and MYCN status. The
other two SNPs were not statistically associated with any of the
prognostic factors examined or clinical outcome (Table S5).
When tri-locus combinations were assessed, estimated frequen-
cies of haplotypes were similar to the ones found in the entire
cohort (Table 4). Strong LD (D9.0.95) was found between all SNP
pairs with the only exception of rs1801725 and rs1801726 (Table
S4). In this sample set, the TAC haplotype was also correlated with
clinical stage 4 (P= 0.012) and inferior OS rates (P= 0.03) (Table
S5 and Figure 1B). Moreover, it was independently associated with
an increased risk of death (Table 4), and this correlation was still
observed among neuroblastoma patients with a follow-up time
longer than three years (HR = 2.38; 95% CI [1.04–5.45];
P= 0.039). An increased risk of events was also seen among
neuroblastoma patients with the TAC haplotype (P= 0.035),
although this association was not statistically significant in
multivariate analyses (Table 4).
Among the subgroup of neuroblastomas without amplification
of the MYCN oncogene (n = 40), the TAC combination was
correlated with inferior EFS rates (P= 0.037). The association with
lower OS rates did not reached statistical significance (P= 0.066).
In multivariate analyses, the TAC haplotype was not an
independent predictor of outcome in this subgroup of neuroblas-
tomas, after adjusting for age at diagnosis, clinical stage and MYCN
amplification status.
Discussion
Over the last decades, somatic alterations associated with
different neuroblastoma phenotypes have been extensively ana-
lyzed. More recently, several genome-wide association studies
have identified susceptibility loci and alleles associated with low- or
high-risk disease. They include variations at FLJ22536 (6p22),
BARD1 (2q35), LMO1 (11p15), HSD17B12 (11p11.2), DUSP12
(1q23.3), LINC00340 (6p22), HACE1 and LIN28B (6q16) [43–49].
These accumulating data would support the hypothesis that
a combination of variants might contribute to the malignant
transformation of embryonal precursor cells from which neuro-
blastic tumors originate, and influence their phenotype. Thus,
benign and malignant forms of neuroblastic tumors might arise as
a result of different initiating genetic events [44,49]. Our present
results would add to this growing body of evidence and further
CaSR Polymorphisms and Neuroblastoma Outcome
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support that genetic variations play a fundamental role in these
developmental malignancies.
We have previously reported that the CaSR gene is expressed in
differentiated, benign neuroblastic tumors but silenced by genetic
and epigenetic events in undifferentiated, unfavorable neuroblas-
tomas. Moreover, upon ectopic overexpression and reactivation of
the CaSR, neuroblastoma cells undergo apoptosis [31–32].
Altogether, these data were consistent with the hypothesis that
the CaSR exerts tumor-suppressor functions in the context of
neuroblastic tumors. To gain further insight into the genetic
mechanisms responsible for its inactivation in aggressive neuro-
blastomas, we have now analyzed three functionally relevant
genetic variants clustered at the carboxyl-terminal tail of the
receptor. They have been analyzed in the context of other
neoplasias mostly as susceptibility loci [24–30]. However, based on
our previous results, we hypothesized that their ability to modify
CaSR function might influence neuroblastoma phenotype and
thus clinical outcome.
Table 1. Association of CaSR gene polymorphisms and haplotypes with clinical and biological features of neuroblastic tumors.
Age* INSS MYCN status INPC
,18 $18 1,2,3,4s 4 NA A Favorable Unfavorable
rs1801725
G/G 16 27 29 14 34 9 25 18
G/T+T/T 8 14 6 16 17 5 8 14
P 0.947 0.002 0.868 0.096
rs1042636
A/A 22 36 32 26 44 14 29 29
A/G+G/G 2 5 3 4 7 0 4 3
P 0.628 0.537 0.142 0.721
rs1801726
C/C 22 39 33 28 13 48 30 31
C/G 2 2 2 2 1 3 3 1
P 0.576 0.873 0.862 0.317
Haplotypes
G-A-C 33 60 58 35 21 72 31 62
T-A-C 10 15 6 19 6 19 12 13
G-G-C 3 5 4 4 0 8 0 8
G-A-G 2 2 2 2 1 3 1 3
P 0.923 0.008 0.499 0.090
*Age at diagnosis: months. INSS: International Neuroblastoma Staging System. MYCN status: A - amplified; NA - not amplified. INPC: International Neuroblastoma
Pathology Classification.
doi:10.1371/journal.pone.0059762.t001
Table 2. Overall and event-free survival of patients diagnosed with neuroblastic tumors according to CaSR genotypes.
OS EFS
Genotype
Cases
(n = 65)
Deaths
(n = 20)
Log-rank
P HR{ (95% CI) P{
Events
(n = 25)
Log-rank
P HR{ (95% CI) P{
rs1801725
G/G 43 9 0.022 1.0 0.183 12 0.01 1.0 0.084
G/T+T/T 22 11 2.217 (0.686–7.158) 13 2.218 (0.114–0.714)
rs1042636
A/A 58 18 0.808 1.0 0.812 23 0.67 1.0 0.831
A/G+G/G 7 2 1.207 (0.255–5.705) 2 0.850 (0.191–3.790)
rs1801726
C/C 61 19 0.99 1.0 0.83 24 0.735 1.0 0.696
C/G 4 1 0.797 (0.101–6.285) 1 0.669 (0.089–5.035)
OS: Overall survival. EFS: Event-free survival.
HR{: Hazard ratio.
{P of Hazard Ratio. CI: Confidence interval.
Multivariate Cox regression model with adjustment for age at diagnosis, clinical stage and MYCN amplification status.
doi:10.1371/journal.pone.0059762.t002
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The cohort analyzed was almost uniformly composed of
patients of Caucasian origin and therefore the most frequent
variant was rs1801725. The frequency of the two other
polymorphisms was not significantly different from other Cauca-
sian populations [50]. Minor allele rs1801725 is thought to
moderately reduce CaSR activity [18,19]. In keeping with our
previous data, this allegedly less active form of the CaSR was
associated with the histological subgroup of undifferentiated
neuroblastomas, metastatic disease and inferior OS rates. How-
ever, it was not an independent predictor of outcome in
multivariate analyses.
Interestingly, when the three polymorphisms were analyzed as
a block, the tri-locus haplotype TAC was correlated with clinical
stage 4 and independently associated with an increased risk of
death in the entire cohort of neuroblastic tumors and, more
importantly, among patients diagnosed with neuroblastomas.
Although the cohort examined is not large, patients have been
diagnosed and treated at a single institution according to
homogeneous criteria. Thus, their outcome is more likely to
depend on clinical features and tumor biology than on manage-
ment. Moreover, the association of this haplotype with poor
outcome was also statistically significant among patients with
a longer follow-up time. However, the frequency of two variants,
rs1042636 and rs1801726, was quite low and limited the statistical
power to detect associations. Thus, validation of our findings in
larger, independent cohorts is warranted. Furthermore, analysis of
patients from different population backgrounds will be necessary
to determine if this haplotype is associated with neuroblastoma
phenotype and outcome in patients of other ethnic origins.
These three SNPs were first suggested to act as a cluster in 1996
[21]. Linkage disequilibrium between them has been repeatedly
reported, a fact that might interfere in the evaluation of specific
functional effects derived from each polymorphism [18]. Scillitani
and colleagues described specific haplotypes at these three loci in
association with blood ionized calcium levels and nephrolitiasis
[22,23]. Functional in vitro analyses to understand the biological
significance of the different haplotypes are lacking. However, it is
tempting to speculate that the TAC combination might encode
a moderately less active form of the CaSR due to the presence of
rs1801725 and the absence of the gain of function produced by
rs1042636. In the context of neuroblastic tumors, the association
of this potentially less active CaSR with metastatic disease and
poor outcome would add to our previous results indicating that
this gene is silenced by genetic and epigenetic mechanisms in
aggressive neuroblastomas.
Several independent predictors of outcome in neuroblastoma
have been reported by other groups and ours [2–4,51–54].
However, high-quality tumor samples and laborious, expensive
techniques are required to analyze most of these genetic and
biological features. Conversely, the analysis of polymorphisms can
Table 3. Overall and event-free survival of patients diagnosed with neuroblastic tumors according to CaSR haplotypes.
OS EFS
Haplotype*
Total
Sample**
(n = 65)
Alive
(n = 45)
Dead
(n = 20) HR{ (95% CI) P{
Event-free
(n = 40)
Event
(n = 25) HR (95% CI) P{
G-A-C 72 77 60 1.00 76 64 1.00
T-A-C 19 13 32 2.45 (1.14–5.29) 0.022 13 30 2.02 (0.99–4.12) 0.052
G-G-C 6 7 5 1.14 (0.22–5.80) 0.868 4 2 0.57 (0.06–5.01) 0.616
G-A-G 3 3 3 0.59 (0.07–5.19) 0.636 8 4 0.81 (0.18–3.71) 0.786
*rs1801725-rs1042636-rs1801726.
**Haplotype estimated frequencies (%). OS: Overall survival. EFS: Event-free survival.
HR{Hazard ratio.
{P of Hazard Ratio. CI: Confidence interval. Multivariate Cox regression model with adjustment for age at diagnosis, clinical stage and MYCN amplification status.
doi:10.1371/journal.pone.0059762.t003
Figure 1. Overall survival probabilities according to CaSR gene haplotypes. Overall survival probabilities of patients diagnosed with (A)
neuroblastic tumors or (B) neuroblastomas according to CaSR gene haplotype at loci rs1801725, rs1042636 and rs1801726.
doi:10.1371/journal.pone.0059762.g001
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be carried out in DNA isolated from any patient’s sample, an
advantage when a biopsy is not feasible, or the quality or quantity
of the available primary tumor is sub-optimal. Moreover, it is
simple to perform and to interpret, highly reproducible and cost-
effective.
In summary, our present data indicate that a tri-locus haplotype
at the signal transduction region of the CaSR might be an
independent predictor of outcome in patients diagnosed with
neuroblastic tumors. Moreover, we provide new evidence
supporting that inactivation of the CaSR gene is a mechanism
associated with neuroblastoma malignant behavior.
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Table S1 Overall and event-free survival of patients diagnosed
with neuroblastic tumors according to clinical and biological
features. Univariate and multivariate analyses were conducted to
analyze overall and event-free survival probabilities in the entire
cohort of patients diagnosed with neuroblastic tumors (n = 65)
according to well-established prognostic factors in these malig-
nancies.
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Table S2 Clinical, histological and biological features of patients
diagnosed with neuroblastic tumors and their genotype at three
polymorphisms of the CaSR gene. The following data are provided
for each patient in the cohort: clinical data at diagnosis (age in
months and clinical stage according to the International
Neuroblastoma Staging System), follow-up data required to
calculate event-free and overall survival probabilities, histological
subgroup, MYCN amplification status and genotype at three CaSR
gene polymorphisms (rs1801725, rs1042636 and rs1801726).
(XLSX)
Table S3 Analysis of departure from Hardy-Weinberg equilib-
rium. Fisher’s exact text was carried out in the entire cohort of
patients diagnosed with neuroblastic tumors (n = 65) and in those
with neuroblastomas (n = 54) to assess if genotype frequencies at
polymorphisms rs1801725, rs1042636 and rs1801726 of the CaSR
gene were in accordance with Hardy-Weinberg equilibrium.
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Table S4 Linkage disequilibrium between loci rs1801725,
rs1042636 and rs1801726 in patients diagnosed with (A)
neuroblastic tumors and (B) neuroblastomas. Linkage disequilib-
rium between polymorphisms pairs was measured through D9 and
r2. These calculations were conducted in the entire cohort of
neuroblastic tumors (A) and in patients diagnosed with neuroblas-
tomas (B).
(XLSX)
Table S5 Association of CaSR gene polymorphisms and
haplotypes with clinical and biological features of neuroblastomas.
Statistical analyses were conducted in neuroblastoma patients
(n = 54) to evaluate associations between single locus genotypes or
tri-locus haplotypes at three CaSR gene polymorphisms
(rs1801725, rs1042636 and rs1801726) and independent prognos-
tic factors in these malignancies (age at diagnosis, clinical stage,
MYCN amplification status and histological subgroup according to
Shimada classification).
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